The 2023 Wave of Novel Therapies: From Blockbuster Drugs to Regulatory Milestones

2023 marks a pivotal year for drug therapy development, with eight novel therapies addressing chronic diseases from hypertension to Alzheimer's reshaping the biotech pipeline landscape.

[IMAGE: Infographic showing the eight drugs with icons for disease area, mechanism, and FDA status]

The pharmaceutical industry entered 2023 with unprecedented momentum. Across therapeutic areas spanning resistant hypertension, retinal disorders, psoriasis, breast cancer, CKD anemia, Alzheimer's disease, and hemophilia, a wave of novel therapies is approaching regulatory decisions and market launches. These candidates represent not just incremental improvements, but fundamentally new mechanisms of action, delivery modalities, and commercial strategies.

Approximately one-third of these therapies are monoclonal antibodies, while the remainder includes oral small molecules, next-generation biologics, and gene therapies. Their peak sales projections range from $0.5 billion to $9.6 billion, reflecting both high unmet medical need and the premium pricing that innovative therapies command. Regulatory milestones—including FDA approvals, priority reviews, and breakthrough designations awarded in 2022 and early 2023—provide a timeline for how these therapies will enter clinical practice.

This article analyzes eight key drugs—Aprocitentan, high-dose Aflibercept, Bimekizumab, Capivasertib, Daprodustat, Deucravacitinib, Donanemab, and Efanesoctocog alfa—to uncover the hidden economic logic, technology trends, and regulatory dynamics driving the 2023 therapeutics revolution.

Novel Mechanisms: Dual Endothelin, TYK2, and HIF-PHI Pathways

The first major theme of 2023 is the emergence of novel oral therapies targeting pathways previously addressed only by injectable biologics. Three drugs exemplify this shift: Aprocitentan, Deucravacitinib, and Daprodustat.

Aprocitentan (Idorsia/Janssen) represents the first dual endothelin receptor antagonist developed for resistant hypertension. This condition affects approximately 10-15% of hypertensive patients who fail to achieve blood pressure control despite taking three or more antihypertensive drugs. The dual mechanism—blocking both endothelin A and B receptors—offers a new approach for patients who have exhausted existing treatment options. Idorsia and Janssen have collaborated on development and commercialization, with peak sales projections reaching $2.5 billion. The FDA action date is expected in 2023, following positive Phase 3 results demonstrating significant blood pressure reductions versus placebo.

[IMAGE: Side-by-side molecular structures of aprocitentan, deucravacitinib, and daprodustat]

Deucravacitinib (BMS/Sotyktu) received FDA approval in September 2022 for moderate-to-severe plaque psoriasis, with European CHMP endorsement in January 2023. As an oral TYK2 inhibitor, Deucravacitinib occupies a unique niche between topical treatments and injectable biologics. TYK2 mediates signaling of interleukin-23, IL-12, and type I interferons, making it a critical node in the inflammatory cascade. BMS projects peak sales of $2.12 billion, positioning it as a potential blockbuster in the psoriasis market. The key advantage: oral administration eliminates injection-related barriers to treatment initiation and adherence.

Daprodustat (GSK/Jesduvroq) received FDA approval in February 2023 for anemia of chronic kidney disease (CKD) in dialysis patients—the first oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor) approved in over 30 years. Previously, CKD anemia treatment relied on injectable erythropoiesis-stimulating agents (ESAs). Daprodustat works by stabilizing HIF, which triggers endogenous erythropoietin production and improves iron utilization. This oral alternative could reduce healthcare costs associated with injection administration and improve patient quality of life.

Implication: The shift from injectable biologics to oral therapies improves patient compliance and reduces healthcare costs. For payers, oral alternatives to expensive infused biologics offer significant budget impact advantages. For patients, the convenience of once-daily oral dosing transforms chronic disease management.

Next-Generation Biologics: Higher Dosing and Dual Targeting

While oral therapies advance, the biologics pipeline is not standing still. Three next-generation biologics demonstrate how innovation continues in injectable formats through higher dosing, extended half-lives, and dual-target mechanisms.

[IMAGE: Timeline comparing dosing frequency of standard vs. high-dose aflibercept and half-life extension for factor VIII]

High-dose Aflibercept (Regeneron/Eylea) represents a significant advancement in retinal disease treatment. The standard 2 mg dose of Aflibercept already achieved $9.6 billion in 2022 sales for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy. The 8 mg formulation, submitted as a BLA in December 2022 with a priority review target date of June 27, 2023, extends dosing intervals from every 8 weeks to every 12-16 weeks. This reduces treatment burden for patients who require repeated intravitreal injections. Regeneron's strategy positions high-dose Aflibercept as a direct competitor to Roche's Vabysmo (faricimab), which already offers extended dosing.

Bimekizumab (UCB) is a dual IL-17A/F inhibitor for psoriasis and hidradenitis suppurativa. Unlike existing IL-17 inhibitors that block only IL-17A (secukinumab, ixekizumab) or IL-17RA (brodalumab), Bimekizumab simultaneously targets both IL-17A and IL-17F, which are key drivers of inflammation in psoriasis. The FDA resubmission was accepted in December 2022 following positive Phase 3 data, with analysts projecting peak sales of $2 billion by 2027. The dual-target mechanism potentially offers superior efficacy, though safety comparisons require longer follow-up.

Efanesoctocog alfa (Sanofi/Sobi) received FDA approval in February 2023 for hemophilia A, marking the first factor VIII replacement therapy with an extended half-life achieved through a next-generation design. The therapy received multiple fast track and breakthrough designations. By extending half-life to approximately 47 hours—significantly longer than standard factor VIII products—Efanesoctocog alfa enables once-weekly prophylaxis dosing. Peak sales are projected at €2.3 billion. This innovation addresses the significant unmet need for hemophilia A patients who require frequent infusions to prevent bleeding episodes.

Analysis: Larger dosing intervals and broader efficacy via dual targets offer competitive advantages in crowded markets. For retinal diseases, every additional week between injections translates to significant patient convenience and clinic capacity improvements. For hemophilia, reduced infusion frequency dramatically improves quality of life while maintaining bleed protection.

Alzheimer’s and the Regulatory Hurdle: Donanemab Faces Scrutiny

The Alzheimer's disease pipeline remains the highest-stakes arena in neurology, and Donanemab (Lilly) exemplifies both the promise and peril of anti-amyloid therapies.

[IMAGE: Timeline of FDA regulatory decisions for Alzheimer's drugs from 2021 to 2023, showing aducanumab controversy and donanemab CRL]

Donanemab, a monoclonal antibody targeting deposited amyloid plaques, received a complete response letter from the FDA in January 2023. The agency cited insufficient exposure data, specifically requiring at least 12 months of drug exposure for at least 100 patients—a standard safety requirement. Peak sales estimates for Donanemab range up to $4.8 billion, reflecting the enormous commercial opportunity in Alzheimer's disease.

This regulatory setback contrasts with Aducanumab's controversial 2021 approval, which set a precedent for accelerated approval based on amyloid reduction as a surrogate endpoint. The contrast between these two cases highlights the FDA's evolving standards for Alzheimer's drug approvals. While Aducanumab faced criticism for ambiguous efficacy data, Donanemab's Phase 2 data showed a statistically significant 32% slowing of cognitive decline—but the FDA has raised the bar for confirmatory evidence.

The regulatory environment for Donanemab will likely be clarified later in 2023 or early 2024, with Lilly submitting additional data from the ongoing TRAILBLAZER-ALZ 2 Phase 3 study. The outcome will have ripple effects across the entire Alzheimer's pipeline, including competing anti-amyloid therapies from Roche and Biogen.

Risk analysis: If Donanemab faces additional delays, it could temper investor enthusiasm for the broader anti-amyloid approach. However, if approved, it would represent a major commercial opportunity and validate the amyloid hypothesis as a viable therapeutic target in Alzheimer's disease.

The Oral vs. Injectable Showdown: Deucravacitinib and Daprodustat Challenge Established Markets

A central competitive dynamic in 2023 is the clash between oral therapies and long-established injectable biologics. Two drugs illustrate this tension: Deucravacitinib versus injectable IL-17 and IL-23 inhibitors for psoriasis, and Daprodustat versus injectable ESAs for CKD anemia.

Deucravacitinib in the psoriasis market faces entrenched competition from injectable biologics including Humira (adalimumab), Stelara (ustekinumab), Cosentyx (secukinumab), and Tremfya (guselkumab). The key question: can an oral therapy match the efficacy of injectable biologics? Deucravacitinib Phase 3 data demonstrated superiority over placebo and non-inferiority to apremilast (Otezla), an oral PDE4 inhibitor with moderate efficacy. However, head-to-head comparisons with IL-17 and IL-23 inhibitors are lacking. The drug's advantage lies in its oral route, which may attract patients hesitant about injections, and its novel mechanism that avoids some safety concerns associated with broader JAK inhibitors.

Daprodustat in the CKD anemia market confronts established ESAs including Epogen (epoetin alfa) and Aranesp (darbepoetin alfa). ESAs have been the standard of care for over 30 years, with well-characterized safety profiles and established dosing protocols. Daprodustat's oral administration offers a compelling alternative, particularly for patients who travel frequently or have limited access to injection clinics. The drug's cardiovascular safety profile will be closely scrutinized, as earlier HIF-PHI candidates faced safety concerns.

[IMAGE: Comparison chart showing oral vs. injectable therapy attributes for psoriasis and CKD anemia]

For investors, the oral vs. injectable competition creates differentiated risk-reward profiles. Oral therapies carry higher commercial potential due to expanded patient access, but face greater regulatory scrutiny for long-term safety. Injectable biologics have proven commercial models but face competition from biosimilars and newer mechanisms.

Valuation and Commercial Prospects: Decoding the Numbers

The commercial prospects of these eight therapies vary dramatically, reflecting different disease populations, pricing dynamics, and competitive landscapes.

| Drug | Company | Indication | Peak Sales Estimate | Key Differentiator | |------|---------|------------|---------------------|---------------------| | High-dose Aflibercept | Regeneron | wAMD, DME | $9.6B (existing franchise) | Extended dosing interval | | Donanemab | Lilly | Alzheimer's | $4.8B | Anti-amyloid antibody | | Aprocitentan | Idorsia/Janssen | Resistant hypertension | $2.5B | First-in-class oral | | Efanesoctocog alfa | Sanofi/Sobi | Hemophilia A | €2.3B | Extended half-life | | Deucravacitinib | BMS | Psoriasis | $2.12B | Oral TYK2 inhibitor | | Bimekizumab | UCB | Psoriasis | $2B | Dual IL-17A/F | | Daprodustat | GSK | CKD anemia | ~$1B | First oral in 30 years | | Capivasertib | AstraZeneca | Breast cancer | ~$0.5B | AKT inhibitor |

Valuation drivers: High-dose Aflibercept benefits from an established commercial infrastructure and existing payer coverage, reducing launch risk. Donanemab and Aprocitentan face greater regulatory and market access uncertainty but address large, underserved populations. Deucravacitinib and Bimekizumab compete in a crowded psoriasis market but offer mechanistic differentiation. Efanesoctocog alfa and Daprodustat address clear unmet needs with well-defined patient populations.

Conclusion: A Transformative Year

The 2023 wave of novel therapies represents more than a collection of individual drug approvals; it signals a structural shift in how chronic diseases are treated. The emergence of oral alternatives to injectable biologics, the extension of dosing intervals through next-generation biologics, and the continued pursuit of disease-modifying therapies for Alzheimer's disease all point toward a future of more convenient, targeted, and effective treatments.

For regulators, the challenge is balancing innovation with safety, particularly for novel mechanisms with limited long-term data. For payers, the question is whether premium pricing for these therapies delivers commensurate value in terms of improved outcomes or reduced healthcare utilization. For patients, the hope is that these therapies translate into better quality of life and disease management.

As FDA action dates approach throughout 2023, the biotech pipeline will reveal which therapies successfully navigate regulatory hurdles, which face additional delays, and which emerge as commercial blockbusters. The answers will shape the pharmaceutical landscape for years to come.